title: Neuropsychological recovery and quality-of-life in children and adolescents with growth hormone deficiency following TBI: a preliminary study.
abstract: OBJECTIVE
  To compare neurocognition and quality-of-life (QoL) in a group of children and adolescents with or without growth hormone deficiency (GHD) following moderate-to-severe traumatic brain injury (TBI).
  
  
  METHODS
  Thirty-two children and adolescents were recruited from the TBI clinic at a children's hospital. Growth hormone (GH) was measured by both spontaneous overnight testing and following arginine/glucagon stimulation administration. Twenty-nine subjects participated in extensive neuropsychological assessment.
  
  
  RESULTS
  GHD as measured on overnight testing was significantly associated with a variety of neurocognitive and QoL measures. Specifically, subjects with GHD had significantly (p < 0.05) lower scores on measures of visual memory and health-related quality-of-life. These scores were not explained by severity of injury or IQ (p > 0.05). GHD noted in response to provocative testing was not associated with any neurocognitive or QoL measures.
  
  
  CONCLUSIONS
  GHD following TBI is common in children and adolescents. Deficits in neurocognition and QoL impact recovery after TBI. It is important to assess potential neurocognitive and QoL changes that may occur as a result of GHD. It is also important to consider the potential added benefit of overnight GH testing as compared to stimulation testing in predicting changes in neurocognition or QoL.
authors: Department of Pediatrics, Riley Children’s Hospital, Indianapolis, IN, USA.
authors: Julia B
authors: JB
authors: Wamstad
authors: Kenneth W
authors: KW
authors: Norwood
authors: Alan D
authors: AD
authors: Rogol
authors: Matthew J
authors: MJ
authors: Gurka
authors: Mark D
authors: MD
authors: Deboer
authors: James A
authors: JA
authors: Blackman
authors: Marcia L
authors: ML
authors: Buck
authors: Michelle N
authors: MN
authors: Kuperminc
authors: Jodi G
authors: JG
authors: Darring
authors: Peter D
authors: PD
authors: Patrick
mesh_terms: D000293:Adolescent; D001120:Arginine / Q000627:therapeutic use; D001930:Brain Injuries / Q000150:complications / Q000188:drug therapy / Q000378:metabolism* / Q000523:psychology*; D002648:Child; D003072:Cognition Disorders / Q000209:etiology / Q000503:physiopathology*; D005260:Female; D005500:Follow-Up Studies; D005934:Glucagon / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000172:deficiency*; D006801:Humans; D008297:Male; D010902:Pituitary Gland / Q000503:physiopathology*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011788:Quality of Life; D020127:Recovery of Function; D055815:Young Adult
chemical_list: D006728:Hormones; D019382:Human Growth Hormone; D005934:Glucagon; D001120:Arginine
references: J Clin Endocrinol Metab. 2004 Oct;89(10):4929-36
references: 15472187
references: J Clin Endocrinol Metab. 1995 May;80(5):1532-40
references: 7538145
references: Neurosurgery. 2008 May;62(5):1080-93; discussion 1093-4
references: 18580806
references: Front Neuroendocrinol. 2000 Oct;21(4):330-48
references: 11013068
references: Brain Inj. 2005 May;19(5):349-58
references: 16094782
references: Growth Horm IGF Res. 2005 Jun;15(3):177-84
references: 15935980
references: Metabolism. 2005 Oct;54(10):1374-83
references: 16154439
references: Neuropsychobiology. 1998;38(2):73-9
references: 9732206
references: J Clin Endocrinol Metab. 1997 Feb;82(2):531-5
references: 9024249
references: J Neurotrauma. 2007 Nov;24(11):1687-97
references: 18001199
references: Clin Endocrinol (Oxf). 2007 Aug;67(2):193-201
references: 17524035
references: Psychoneuroendocrinology. 1998 Jan;23(1):57-63
references: 9618752
references: Psychoneuroendocrinology. 2006 Jul;31(6):681-91
references: 16621325
references: Growth Horm IGF Res. 2008 Dec;18(6):472-8
references: 18829359
references: J Neuropsychiatry Clin Neurosci. 2007 Fall;19(4):363-72
references: 18070838
references: J Neurotrauma. 2007 Jan;24(1):119-27
references: 17263675
references: J Clin Endocrinol Metab. 2000 Nov;85(11):3990-3
references: 11095419
references: Growth Horm IGF Res. 2004 Jun;14(3):185-94
references: 15125879
references: J Clin Endocrinol Metab. 1998 Sep;83(9):3184-9
references: 9745423
references: Horm Res. 2002;58(5):233-41
references: 12401943
references: Neuropsychobiology. 2000 Jan;41(2):73-8
references: 10644927
references: J Neurotrauma. 2005 Sep;22(9):937-46
references: 16156709
references: Brain Inj. 2005 Aug 20;19(9):711-24
references: 16195185
references: Brain Inj. 2007 Jul;21(8):871-5
references: 17676444
references: Eur J Pharmacol. 2004 Apr 19;490(1-3):97-113
references: 15094077
references: Trends Endocrinol Metab. 2004 Aug;15(6):252-8
references: 15358277
references: Neuroendocrinology. 2005;82(1):32-40
references: 16330884
references: Growth Horm IGF Res. 2004 Jun;14 Suppl A:S108-13
references: 15135790
references: J Neurotrauma. 2004 Jun;21(6):685-96
references: 15253797
references: Neurobiol Aging. 2011 Nov;32(11):1942-8
references: 20031276
references: Growth Horm IGF Res. 2002 Oct;12(5):323-41
references: 12213187
references: Neuroendocrinology. 2006;83(1):12-9
references: 16707911
references: J Clin Endocrinol Metab. 2005 Nov;90(11):6085-92
references: 16144947
references: J Pediatr. 2008 Apr;152(4):590-3
references: 18346522
references: J Clin Endocrinol Metab. 1996 Mar;81(3):1063-8
references: 8772577
references: Ageing Res Rev. 2005 May;4(2):195-212
references: 16024298
references: Growth Horm IGF Res. 2004 Jun;14 Suppl A:S114-7
references: 15135791